Madrigal Pharmaceuticals
$499.40Change from previous close: −0.06%Absolute change: −$0.31
At a glance
- Revenue growth
- +432.05%
- 2025 vs 2024
- Net margin
- -30.1%
- 2024: -258.6%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total revenue | 364 | 311 | 321 | 287 | 213 |
| Cost of revenue | 40.0 | 26.8 | 24.4 | 18.1 | 9.1 |
| Gross profit | 324 | 284 | 297 | 269 | 204 |
| Selling, general and administrative | 289 | 269 | 240 | 209 | 197 |
| Research and development | 91.2 | 109 | 116 | 174 | 54.1 |
| Operating income | -56.3 | -92.7 | -59.6 | -114 | -47.2 |
| EBIT | -50.0 | -86.6 | -50.3 | -107 | -39.0 |
| EBITDA | -49.6 | -86.2 | -49.9 | -106 | -38.6 |
| Interest expense | 7.9 | 7.8 | 8.3 | 7.5 | 3.3 |
| Pre-tax income | -57.9 | -94.4 | -58.6 | -114 | -42.3 |
| Net income | -57.9 | -94.4 | -58.6 | -114 | -42.3 |
| Net income to common shareholders | -57.9 | -94.4 | -58.6 | -114 | -42.3 |
| Basic EPS | -1.99 | -3.25 | -2.57 | -5.08 | -1.50 |
| Diluted EPS | -1.99 | -3.25 | -2.57 | -5.08 | -1.50 |
| Average shares (basic) | 29.1 | 29.0 | 22.8 | 22.5 | 28.2 |
| Average shares (diluted) | 29.1 | 29.0 | 22.8 | 22.5 | 28.2 |